BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20462211)

  • 21. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
    Lee J; Seo HJ; Lee SH; Kim J; Jung ME; Lee SH; Song KS; Lee J; Kang SY; Kim MJ; Kim MS; Son EJ; Lee M; Han HK
    Bioorg Med Chem; 2010 Sep; 18(17):6377-88. PubMed ID: 20673729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
    Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
    Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
    Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
    Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human chymase inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold.
    Groutas WC; Schechter NM; He S; Yu H; Huang P; Tu J
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2199-204. PubMed ID: 10465545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
    Carlier PR; Lo MM; Lo PC; Richelson E; Tatsumi M; Reynolds IJ; Sharma TA
    Bioorg Med Chem Lett; 1998 Mar; 8(5):487-92. PubMed ID: 9871604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
    Shao L; Wang F; Malcolm SC; Ma J; Hewitt MC; Campbell UC; Bush LR; Spicer NA; Engel SR; Saraswat LD; Hardy LW; Koch P; Schreiber R; Spear KL; Varney MA
    Bioorg Med Chem; 2011 Jan; 19(1):663-76. PubMed ID: 21093273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
    Maw GN; Stobie A; Planken S; Pryde DC; Sanderson V; Platts MY; Corless M; Stacey P; Wayman C; Van Der Graaf P; Kohl C; Coggon S; Beaumont K
    Chem Biol Drug Des; 2006 Jan; 67(1):74-7. PubMed ID: 16492151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
    Paudel S; Min X; Acharya S; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2017 Oct; 25(20):5278-5289. PubMed ID: 28807575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.
    Lucas MC; Weikert RJ; Carter DS; Cai HY; Greenhouse R; Iyer PS; Lin CJ; Lee EK; Madera AM; Moore A; Ozboya K; Schoenfeld RC; Steiner S; Zhai Y; Lynch SM
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5559-66. PubMed ID: 20691589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives.
    Jeppesen L; Olesen PH; Hansen L; Sheardown MJ; Thomsen C; Rasmussen T; Jensen AF; Christensen MS; Rimvall K; Ward JS; Whitesitt C; Calligaro DO; Bymaster FP; Delapp NW; Felder CC; Shannon HE; Sauerberg P
    J Med Chem; 1999 Jun; 42(11):1999-2006. PubMed ID: 10354408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.
    Charrier N; Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; East P; Hawkins J; Howes C; Hussain I; Jeffrey P; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
    J Med Chem; 2008 Jun; 51(11):3313-7. PubMed ID: 18457381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a novel class of zwitterionic, potent, selective and orally active S1P₁ direct agonists.
    Aguilar N; Mir M; Grima PM; López M; Segarra V; Esteban L; Moreno I; Godessart N; Tarrasón G; Domenech T; Vilella D; Armengol C; Córdoba M; Sabaté M; Casals D; Domínguez M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7672-6. PubMed ID: 23141913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
    J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity.
    Keown LE; Collins I; Cooper LC; Harrison T; Madin A; Mistry J; Reilly M; Shaimi M; Welch CJ; Clarke EE; Lewis HD; Wrigley JD; Best JD; Murray F; Shearman MS
    J Med Chem; 2009 Jun; 52(11):3441-4. PubMed ID: 19432431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
    Kolhatkar RB; Ghorai SK; George C; Reith ME; Dutta AK
    J Med Chem; 2003 May; 46(11):2205-15. PubMed ID: 12747792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.
    Paudel S; Sun N; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2018 Aug; 26(14):4127-4135. PubMed ID: 30007567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.